<p>圣地亚哥 --（商业资讯）--Travere Therapeutics, Inc.（纳斯达克：TVTX）今天宣布，在 2025 年 12 月 10 日，其董事会薪酬委员会向五名新员工授予了诱导性股权奖励，包括诱导性限制性股票单位（RSUs），总计覆盖 20,300 股普通股。这些诱导性 RSUs 受 Travere 2018 年股权激励计划（“2018 计划”）的条款约束，但是在 2018 计划之外授予的，并作为新员工入职 Travere 的诱导措施，符合纳斯达克上市规则 5635(c)(4) 的规定。</p>
<p>这些 RSUs 在四年内逐步归属，授予日期每周年 25% 的股份归属，前提是新员工在适用的归属日期之前与 Travere 保持持续的服务关系。</p>
<p><strong>关于 Travere Therapeutics</strong></p>
<p>在 Travere Therapeutics，我们致力于罕见疾病的生命。我们是一家生物制药公司，每天聚集在一起，帮助各类背景的患者、家庭和护理人员应对罕见疾病带来的生活挑战。在这条道路上，我们知道治疗选择的需求是迫切的——这就是为什么我们的全球团队与罕见疾病社区合作，识别、开发和提供改变生命的疗法。为了实现这一使命，我们不断寻求理解罕见患者的多样化视角，并勇敢地开辟新路径，以改变他们的生活并提供希望——今天和明天。有关更多信息，请访问 travere.com。</p>
<p><img src="https://imageproxy.pbkrs.com/https://cts.businesswire.com/ct/CT/query-ZGlzdHJvPW54JmlkPWJ3bmV3cyZsYW5nPWVuJnNpZD1hY3FyOCZzdHk9MjAyNTEyMTE3Nzk0MjVyMQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://cts.businesswire.com/ct/CT/query-ZGlzdHJvPW54JmlkPWJ3bmV3cyZsYW5nPWVuJnNpZD1hY3FyOCZzdHk9MjAyNTEyMTE3Nzk0MjVyMQ"/></p>
<p>在 businesswire.com 查看源版本：https://www.businesswire.com/news/home/20251211779425/en/</p>
<p>媒体：</p>
<p>888-969-7879</p>
<p>mediarelations@travere.com</p>
<p>投资者：</p>
<p>888-969-7879</p>
<p>IR@travere.com</p>
<p>来源：Travere Therapeutics, Inc.</p>

TVTX

<p>Travere Therapeutics 宣布根据纳斯达克上市规则 5635(c)(4) 向五名新员工授予诱导性股权奖励，共计 20,300 股限制性股票单位（RSUs）。这些 RSUs 是在 2018 年股权激励计划之外授予的，需在四年内逐步解锁，前提是员工继续服务。Travere 专注于开发罕见疾病的治疗方案</p>

<p>SAN DIEGO--(BUSINESS WIRE)--Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that on December 10, 2025, the Compensation Committee of its Board of Directors granted inducement equity grants to five new employees, consisting of inducement restricted stock units, or RSUs, covering an aggregate of 20,300 shares of its common stock. These inducement RSUs are subject to the terms of Travere’s 2018 Equity Incentive Plan (“2018 Plan”) but were granted outside of the 2018 Plan and were granted as inducements material to the new employees entering into employment with Travere in accordance with Nasdaq Listing Rule 5635(c)(4).</p>
<div class="lb-trans"><p>圣地亚哥 --（商业资讯）--Travere Therapeutics, Inc.（纳斯达克：TVTX）今天宣布，在 2025 年 12 月 10 日，其董事会薪酬委员会向五名新员工授予了诱导性股权奖励，包括诱导性限制性股票单位（RSUs），总计覆盖 20,300 股普通股。这些诱导性 RSUs 受 Travere 2018 年股权激励计划（“2018 计划”）的条款约束，但是在 2018 计划之外授予的，并作为新员工入职 Travere 的诱导措施，符合纳斯达克上市规则 5635(c)(4) 的规定。</p>
</div><p>The RSUs vest over four years, with 25% of the shares vesting on each anniversary of the grant date, subject to the new employee’s continued service relationship with Travere through the applicable vesting dates.</p>
<div class="lb-trans"><p>这些 RSUs 在四年内逐步归属，授予日期每周年 25% 的股份归属，前提是新员工在适用的归属日期之前与 Travere 保持持续的服务关系。</p>
</div><p><strong>About Travere Therapeutics</strong></p>
<div class="lb-trans"><p><strong>关于 Travere Therapeutics</strong></p>
</div><p>At Travere Therapeutics, we are in rare for life. We are a biopharmaceutical company that comes together every day to help patients, families and caregivers of all backgrounds as they navigate life with a rare disease. On this path, we know the need for treatment options is urgent – that is why our global team works with the rare disease community to identify, develop and deliver life-changing therapies. In pursuit of this mission, we continuously seek to understand the diverse perspectives of rare patients and to courageously forge new paths to make a difference in their lives and provide hope – today and tomorrow. For more information, visit travere.com.</p>
<div class="lb-trans"><p>在 Travere Therapeutics，我们致力于罕见疾病的生命。我们是一家生物制药公司，每天聚集在一起，帮助各类背景的患者、家庭和护理人员应对罕见疾病带来的生活挑战。在这条道路上，我们知道治疗选择的需求是迫切的——这就是为什么我们的全球团队与罕见疾病社区合作，识别、开发和提供改变生命的疗法。为了实现这一使命，我们不断寻求理解罕见患者的多样化视角，并勇敢地开辟新路径，以改变他们的生活并提供希望——今天和明天。有关更多信息，请访问 travere.com。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://cts.businesswire.com/ct/CT/query-ZGlzdHJvPW54JmlkPWJ3bmV3cyZsYW5nPWVuJnNpZD1hY3FyOCZzdHk9MjAyNTEyMTE3Nzk0MjVyMQ" alt="" original-src="https://cts.businesswire.com/ct/CT?id=bwnews&amp;sty=20251211779425r1&amp;sid=acqr8&amp;distro=nx&amp;lang=en"/></p>
<p>View source version on businesswire.com: https://www.businesswire.com/news/home/20251211779425/en/</p>
<div class="lb-trans"><p>在 businesswire.com 查看源版本：https://www.businesswire.com/news/home/20251211779425/en/</p>
</div><p>Media:</p>
<div class="lb-trans"><p>媒体：</p>
</div><p>888-969-7879</p>
<div class="lb-trans"><p>888-969-7879</p>
</div><p>mediarelations@travere.com</p>
<div class="lb-trans"><p>mediarelations@travere.com</p>
</div><p>Investors:</p>
<div class="lb-trans"><p>投资者：</p>
</div><p>888-969-7879</p>
<div class="lb-trans"><p>888-969-7879</p>
</div><p>IR@travere.com</p>
<div class="lb-trans"><p>IR@travere.com</p>
</div><p>Source: Travere Therapeutics, Inc.</p>
<div class="lb-trans"><p>来源：Travere Therapeutics, Inc.</p>
</div>

Travere Therapeutics 根据纳斯达克上市规则 5635(c)(4) 报告了诱导性授予 | TVTX 股票新闻